NewLink Genetics Corp and Lumos Pharma Inc Enters Into A Definitive Merger Agreement - Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the NewLink Genetics and Lumos Pharma Merger Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now turn the call over to Lisa Miller, Director of Investor Relations at NewLink Genetics. You may begin, ma'am.
Thank you. I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. Federal securities law. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |